Quantum biochemistry in cancer immunotherapy: New insights about CTLA-4/ipilimumab and design of ipilimumab-derived peptides with high potential in cancer treatment-Reference-Cited by-同舟云学术

Quantum biochemistry in cancer immunotherapy: New insights about CTLA-4/ipilimumab and design of ipilimumab-derived peptides with high potential in cancer treatment

Published:2020-11 Issue: Volume:127 Page:203-211
ISSN:0161-5890
Container-title:Molecular Immunology
language:en
Short-container-title:Molecular Immunology

Author:

Amaral Jackson L.,Santos Samuel J.M.,Souza Pedro F.N.,de Morais Pablo A.,Maia F.F.,Carvalho Hernandes F.,Freire Valder N.

Funder

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Publisher

Elsevier BV

Subject

Molecular Biology,Immunology

Reference30 articles.

1. Structure-function analysis of immune checkpoint receptors to guide emerging anticancer immunotherapy;Acúrcio;J. Med. Chem.,2018

2. Progress and challenges in the design and clinical development of antibodies for Cancer therapy;Almagro;Front. Immunol.,2017

3. Selective anticancer activity of synthetic peptides derived from the host defence peptide tritrpticin;Arias;Biochim. Biophys. Acta Biomembr.,2020

4. An efficient approach for ab initio energy calculation of biopolymers;Chen;J. Chem. Phys.,2005

5. From molecules to solids with the DMol3 approach;Delley;J. Chem. Phys.,2000

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tofacitinib and peficitinib inhibitors of Janus kinase for autoimmune disease treatment: a quantum biochemistry approach;Physical Chemistry Chemical Physics;2024

2. Immune-oncological drug ipilimumab;Quantum Chemistry Methods for Oncological Drugs;2024

3. Recalculating the Route: Repositioning Antimicrobial Peptides for Cancer Treatment;Chemistry & Biodiversity;2023-12-13

4. Plant protease inhibitors against SARS-CoV-2 main protease: an in silico approach;Future Virology;2023-05

5. Patient-derived organoids in translational oncology and drug screening;Cancer Letters;2023-05